Sanofi (SNYNF) Interest Expenses (2009 - 2026)

Sanofi has disclosed Interest Expenses across 18 years of filings, most recently posting -$208.4 million for Q1 2026.

• Interest Expenses for Q1 2026 came in at -$208.4 million, up 6.99% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.7 billion (up 14.6% YoY), and the FY2025 annual result was $655.4 million, down 42.84% from the prior year.
• Interest Expenses came in at -$208.4 million for Q1 2026 at Sanofi, up from -$655.4 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of -$98.8 million in Q1 2022 to a low of -$1.4 billion in Q4 2023.
• The 5-year median for Interest Expenses is -$268.3 million (2024), against an average of -$405.7 million.
• Across the five-year window, Interest Expenses slumped 233.33% in 2023 and soared 53.7% in 2025, its largest moves.
• Sanofi's Interest Expenses stood at -$448.9 million in 2022, then plunged by 209.9% to -$1.4 billion in 2023, then grew by 17.58% to -$1.1 billion in 2024, then soared by 42.84% to -$655.4 million in 2025, then surged by 68.2% to -$208.4 million in 2026.
• The last three Interest Expenses figures came in at -$208.4 million (Q1 2026), -$655.4 million (Q4 2025), and -$687.4 million (Q3 2025), per Business Quant data.